Dr Thomas Hefti is joining as Chief Executive Officer of Bottneuro AG, Switzerland as of June 1. Dr Bekim Osmani, co-founder and current CEO, will assume the role as Group CEO and Chairman of the Board.
Bottneuro announced today that Dr Thomas Hefti is joining Bottneuro AG as Chief Executive Officer. Thomas has an extensive track record of commercial success in both the pharmaceutical and the medical device industry. Most recently he acted as the leader for the international business of Novocure, an innovative Switzerland-based medical device company.
«I am very excited to join Bottneuro at this important moment, bringing the Miamind® neurostimulator, a personalized, custom-made medical device, to patients suffering from neurcognitive disorders, in particular Alzheimer’s Disease», states Thomas who is soon to join the highly engaged Bottneuro team at the Swiss Innovation Park in Basel.
Dr Bekim Osmani, co-founder and currently Chief Executive Officer, will assume the role of Group CEO and Chairman of the Board. Bekim states «I am very pleased to have Thomas on board, bringing along highly needed expertise ensuring future success of Bottneuro.»
To learn more about the Miamind® neurostimulator please visit miamind.ch!
About Bottneuro
Bottneuro is a commercial‑stage spin‑off from the Department of Biomedical Engineering at the University of Basel. We develop and market Miamind®, an innovative neurostimulator that delivers personalized, non‑invasive, home‑based transcranial electrical stimulation (tES) to improve the lives of people with cognitive disorders.
About Miamind® Neurostimulator – Personalised Brain Therapy at Home
The Miamind® Neurostimulator, registered as custom-made medical device according to ANNEX XIII EU-MDR, is a modern non-invasive transcranial electrical stimulation (tES) and electroencephalography (EEG) device for personalised, non-invasive brain stimulation. Up to 34, freely placeable electrodes allow complete personalisation and ensure high treatment focality. Each device is custom-made to account for the patient’s unique anatomy. To ensure comfortable fit, good electrode-scalp contact and precise location of the electrodes, each device is 3D printed based on the individuals anatomical MRI scans. The Miamind® Neurostimulator is commercially available in the EU, UK, and Switzerland.